Pay By Phone online casinos are revolutionizing the gaming industry. As digital banking and payments become an ever larger part of our lives, it's no wonder.
Investors 1
| Date | Name | Website |
| - | Fountain H... | fh-partner... |
Mentions in press and media 5
| Date | Title | Description |
| 08.03.2016 | Genable Technologies Investors Secure Spark Exit | Venture capital investors in TCD campus company Genable Technologies have secured an exit from the loss-making firm through the sale of the business to Nasdaq-quoted Spark Therapeutics. As of February 2015, Genable had capital invested of €... |
| 09.01.2015 | Irish VC Fountain Healthcare launches $127.5M fund | –Chrono Therapeutics, a Bay Area digital smoking cessation startup –Innocoll, an Irish maker of biodegradable surgical implants and topical adhesives to treat post-op pain and diabetic foot ulcers. Its previous investments include: –Civitas... |
| 25.03.2014 | Gene therapy company Spark Therapeutics inks licensing deal for a retinitis pigmentosa gene therapy | Rhodopsin-linked autosomal dominant retinitis pigmentosa affects roughly 30,000 people worldwide and there are currently no drugs to treat it. Genable’s retinitis pigmentosa gene therapy is designed to suppresses the expression of faulty an... |
| - | Irish VC Fountain Healthcare launches $127.5M fund | Fountain Healthcare Partners just closed its second fund, with €85 million – or about $127.5 million. The Irish VC firm – which has offices in New York – plans to make 10 to 15 investments in the fields of specialty pharma, biotech, medical... |
| - | Gene therapy company Spark Therapeutics inks licensing deal for a retinitis pigmentosa gene therapy | Retinitis pigmentosa is the most common inherited eye disease. Mutations in the gene for rhodopsin, the pigment for photoreceptor cells in the retina responsible for the perception of light, account for 15 percent of retinitis pigmentosa ca... |